Evaluation of Fractionated Photofrin-mediated Photodynamic Therapy Using Different Light Fluences with Reactive Oxygen Species Explicit Dosimetry (ROSED)

Overview

Journal Proc SPIE Int Soc Opt Eng

Date 2023 Jun 28

PMID 37378071

Authors

Hongjing Sun

Vivek Rastogi

Timothy C Zhu

Affiliations

Soon will be listed here.

Abstract

Photodynamic therapy (PDT) is an established modality for cancer treatment, and reactive oxygen species explicit dosimetry (ROSED), based on direct measurements of in-vivo light fluence (rate), in-vivo photofrin concentration, and tissue oxygenation concentration, has been proved to provide the best dosimetric quantity which can be used to predict non-fractionated PDT outcome. This study performed ROSED for Photofrin-mediated PDT for mice bearing radiation-induced fibrosacorma (RIF) tumor. As demonstrated by our previous study, fractionated PDT with a 2-hour time interval can significantly improve the long-term cure rate (from 15% to 65% at 90 days), and it tends to increase as the light dose for the first light fraction gets larger. This study focused on further improving the long-term cure rate without introducing apparent toxicity using combinations of different first light fraction lengths and total light fluences. Photofrin was injected through the mouse tail vein at a concentration of 5 mg/kg. After 18~24 hours, treatment was delivered with a collimated laser beam of 1 cm diameter at 630 nm. Mice were treated using two fractions of light fluences with a 2-hour dark interval. Different dose metrics were quantified, including light fluence, PDT dose, and [ROS]rx. In addition, the total reacted [ROS]rx and treatment outcomes were evaluated and compared to identify the optimal light fraction length and total light fluence.

References

Kim M, Penjweini R, Zhu T . Evaluation of singlet oxygen explicit dosimetry for predicting treatment outcomes of benzoporphyrin derivative monoacid ring A-mediated photodynamic therapy. J Biomed Opt. 2017; 22(2):28002. PMC: 5301138. DOI: 10.1117/1.JBO.22.2.028002. View

Sheng T, Ong Y, Busch T, Zhu T . Reactive oxygen species explicit dosimetry to predict local tumor control for Photofrin-mediated photodynamic therapy. Proc SPIE Int Soc Opt Eng. 2019; 10860. PMC: 6639794. DOI: 10.1117/12.2508803. View

Robinson D, de Bruijn H, Star W, Sterenborg H . Dose and timing of the first light fraction in two-fold illumination schemes for topical ALA-mediated photodynamic therapy of hairless mouse skin. Photochem Photobiol. 2003; 77(3):319-23. DOI: 10.1562/0031-8655(2003)077<0319:DATOTF>2.0.CO;2. View

de Bruijn H, Casas A, Di Venosa G, Gandara L, Sterenborg H, Batlle A . Light fractionated ALA-PDT enhances therapeutic efficacy in vitro; the influence of PpIX concentration and illumination parameters. Photochem Photobiol Sci. 2012; 12(2):241-5. DOI: 10.1039/c2pp25287b. View

Sun H, Ong Y, Zhu T . Reactive oxygen species explicit dosimetry (ROSED) for fractionated photofrin-mediated photodynamic therapy (PDT). Proc SPIE Int Soc Opt Eng. 2022; 11940. PMC: 9075689. DOI: 10.1117/12.2609969. View

Busch T, Xing X, Yu G, Yodh A, Wileyto E, Wang H . Fluence rate-dependent intratumor heterogeneity in physiologic and cytotoxic responses to Photofrin photodynamic therapy. Photochem Photobiol Sci. 2009; 8(12):1683-93. PMC: 2834171. DOI: 10.1039/b9pp00004f. View

de Bruijn H, van der Ploeg-van den Heuvel A, Sterenborg H, Robinson D . Fractionated illumination after topical application of 5-aminolevulinic acid on normal skin of hairless mice: the influence of the dark interval. J Photochem Photobiol B. 2006; 85(3):184-90. DOI: 10.1016/j.jphotobiol.2006.07.004. View

Ong Y, Kim M, Huang Z, Zhu T . Reactive Oxygen Species Explicit Dosimetry (ROSED) of a Type 1 Photosensitizer. Proc SPIE Int Soc Opt Eng. 2018; 10476. PMC: 5975967. DOI: 10.1117/12.2291385. View

Qiu H, Kim M, Penjweini R, Zhu T . Macroscopic singlet oxygen modeling for dosimetry of Photofrin-mediated photodynamic therapy: an in-vivo study. J Biomed Opt. 2016; 21(8):88002. PMC: 5331118. DOI: 10.1117/1.JBO.21.8.088002. View

10.

Ong Y, Kim M, Finlay J, Dimofte A, Singhal S, Glatstein E . PDT dose dosimetry for Photofrin-mediated pleural photodynamic therapy (pPDT). Phys Med Biol. 2017; 63(1):015031. PMC: 5952607. DOI: 10.1088/1361-6560/aa9874. View

11.

Curnow A, MacRobert A, Bown S . Comparing and combining light dose fractionation and iron chelation to enhance experimental photodynamic therapy with aminolevulinic acid. Lasers Surg Med. 2006; 38(4):325-31. DOI: 10.1002/lsm.20328. View

12.

Ong Y, Miller J, Yuan M, Chandra M, Khatib M, Vinogradov S . Blood Flow Measurements Enable Optimization of Light Delivery for Personalized Photodynamic Therapy. Cancers (Basel). 2020; 12(6). PMC: 7353010. DOI: 10.3390/cancers12061584. View

13.

Sheng T, Ong Y, Guo W, Zhu T . Reactive oxygen species explicit dosimetry to predict tumor growth for benzoporphyrin derivative-mediated vascular photodynamic therapy. J Biomed Opt. 2020; 25(6):1-13. PMC: 6952881. DOI: 10.1117/1.JBO.25.6.063805. View